Latest News

Evidence mounting that full-body emollients don’t prevent AD in at-risk babies

Publish date: October 24, 2022

 

AT ISAD 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Study identifies skin biomarkers that predict newborn eczema risk
MDedge Dermatology
BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported
MDedge Dermatology
52-week data show lebrikizumab atopic dermatitis effects maintained
MDedge Dermatology
Petrolatum Is Effective as a Moisturizer, But There Are More Uses for It
MDedge Dermatology
Dupilumab study outlines benefits, safety profile in infants, preschoolers with atopic dermatitis
MDedge Dermatology
Dermatologists fear effects of Dobbs decision for patients on isotretinoin, methotrexate
MDedge Dermatology
Climate change: Commentary in four dermatology journals calls for emergency action
MDedge Dermatology
Vaccinium myrtillus (bilberry seed oil) extract
MDedge Dermatology
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Dermatology
Study finds systemic AD treatment relieves depressive symptoms along with skin symptoms
MDedge Dermatology